{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:55:07Z","timestamp":1791388507409,"version":"4.3.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS136677"],"award-info":[{"award-number":["R01NS136677"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AU-2127-20220331"],"award-info":[{"award-number":["AU-2127-20220331"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM145232"],"award-info":[{"award-number":["R35GM145232"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Will Erwin Headache Research Center"},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG065984"],"award-info":[{"award-number":["R01AG065984"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02008-0","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:04:49Z","timestamp":1747983889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity"],"prefix":"10.1186","volume":"26","author":[{"given":"Chorong","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwayoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Ye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia K.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Burish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2008_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/B978-0-12-823357-3.00008-2","volume":"199","author":"M Whealy","year":"2024","unstructured":"Whealy M, Becker WJ (2024) The 5-HT(1B) and 5-HT(1D) agonists in acute migraine therapy: ergotamine, Dihydroergotamine, and the triptans. Handb Clin Neurol 199:17\u201342","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"2008_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1526-4610.2010.01662.x","volume":"50","author":"EP Baron","year":"2010","unstructured":"Baron EP, Tepper SJ (2010) Revisiting the role of ergots in the treatment of migraine and headache. Headache 50(8):1353\u20131361","journal-title":"Headache"},{"issue":"10","key":"2008_CR3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/ene.15956","volume":"30","author":"A May","year":"2023","unstructured":"May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, Carvalho V, Romoli M, Aleksovska K, Pozo-Rosich P et al (2023) European academy of neurology guidelines on the treatment of cluster headache. Eur J Neurol 30(10):2955\u20132979","journal-title":"Eur J Neurol"},{"issue":"7","key":"2008_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039","journal-title":"Headache"},{"issue":"1","key":"2008_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV (2021) D\u2019Souza DC: exploratory controlled study of the Migraine-Suppressing effects of psilocybin. Neurotherapeutics 18(1):534\u2013543","journal-title":"Neurotherapeutics"},{"key":"2008_CR6","doi-asserted-by":"publisher","first-page":"122993","DOI":"10.1016\/j.jns.2024.122993","volume":"460","author":"EAD Schindler","year":"2024","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, Cozzi NV, D\u2019Souza DC (2024) Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci 460:122993","journal-title":"J Neurol Sci"},{"issue":"8","key":"2008_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol 18(8):795\u2013804","journal-title":"Lancet Neurol"},{"key":"2008_CR8","doi-asserted-by":"crossref","unstructured":"Verhoeff NP, Visser WH, Ferrari MD, Saxena PR, van Royen EA (1993) Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Cephalalgia. 13(5):325\u2013329","DOI":"10.1046\/j.1468-2982.1993.1305325.x"},{"issue":"3","key":"2008_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1468-2982.1982.0203145.x","volume":"2","author":"H Hovdal","year":"1982","unstructured":"Hovdal H, Syversen GB, Rosenthaler J (1982) Ergotamine in plasma And CSF after I.m. And rectal administration to humans. Cephalalgia 2(3):145\u2013150","journal-title":"Cephalalgia"},{"issue":"2","key":"2008_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/head.14670","volume":"64","author":"C Han","year":"2024","unstructured":"Han C, Lim JY, Koike N, Kim SY, Ono K, Tran CK, Mangutov E, Kim E, Zhang Y, Li L et al (2024) Regulation of headache response and transcriptomic network by the trigeminal ganglion clock. Headache 64(2):195\u2013210","journal-title":"Headache"},{"issue":"3","key":"2008_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrg.2016.150","volume":"18","author":"JS Takahashi","year":"2017","unstructured":"Takahashi JS (2017) Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet 18(3):164\u2013179","journal-title":"Nat Rev Genet"},{"issue":"15","key":"2008_CR12","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1073\/pnas.0308709101","volume":"101","author":"SH Yoo","year":"2004","unstructured":"Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, Siepka SM, Hong HK, Oh WJ, Yoo OJ et al (2004) PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A 101(15):5339\u20135346","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"2008_CR13","doi-asserted-by":"publisher","first-page":"E8855","DOI":"10.1073\/pnas.1706611114","volume":"114","author":"SH Yoo","year":"2017","unstructured":"Yoo SH, Kojima S, Shimomura K, Koike N, Buhr ED, Furukawa T, Ko CH, Gloston G, Ayoub C, Nohara K et al (2017) Period2 3\u2019-UTR and microRNA-24 regulate circadian rhythms by repressing PERIOD2 protein accumulation. Proc Natl Acad Sci U S A 114(42):E8855\u2013E8864","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2008_CR14","doi-asserted-by":"publisher","first-page":"1142785","DOI":"10.3389\/fnins.2023.1142785","volume":"17","author":"Y Shirakawa","year":"2023","unstructured":"Shirakawa Y, Ohno SN, Yamagata KA, Kuramoto E, Oda Y, Nakamura TJ, Nakamura W, Sugimura M (2023) Circadian rhythm of PERIOD2::LUCIFERASE expression in the trigeminal ganglion of mice. Front Neurosci 17:1142785","journal-title":"Front Neurosci"},{"issue":"22","key":"2008_CR15","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1212\/WNL.0000000000207240","volume":"100","author":"B Benkli","year":"2023","unstructured":"Benkli B, Kim SY, Koike N, Han C, Tran C, Silva E, Yan Y, Yagita K, Chen Z, Yoo SH et al (2023) Circadian features of cluster headache and migraine: A systematic review, Meta-analysis, and genetic analysis. Neurology 100(22):e2224\u2013e2236","journal-title":"Neurology"},{"issue":"1\u20132","key":"2008_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2013.05.012","volume":"380","author":"T Dickmeis","year":"2013","unstructured":"Dickmeis T, Weger BD, Weger M (2013) The circadian clock and glucocorticoids\u2013interactions across many time scales. Mol Cell Endocrinol 380(1\u20132):2\u201315","journal-title":"Mol Cell Endocrinol"},{"key":"2008_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/NSS.S158602","volume":"10","author":"D Meneses-Santos","year":"2018","unstructured":"Meneses-Santos D, Buonfiglio DDC, Peliciari-Garcia RA, Ramos-Lobo AM, Souza DDN, Carpinelli AR, Carvalho CRO, Sertie RAL, Andreotti S, Lima FB et al (2018) Chronic treatment with dexamethasone alters clock gene expression and melatonin synthesis in rat pineal gland at night. Nat Sci Sleep 10:203\u2013215","journal-title":"Nat Sci Sleep"},{"issue":"12","key":"2008_CR18","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1093\/nar\/gkt307","volume":"41","author":"S Cheon","year":"2013","unstructured":"Cheon S, Park N, Cho S, Kim K (2013) Glucocorticoid-mediated Period2 induction delays the phase of circadian rhythm. Nucleic Acids Res 41(12):6161\u20136174","journal-title":"Nucleic Acids Res"},{"issue":"5763","key":"2008_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1121613","volume":"311","author":"L Yin","year":"2006","unstructured":"Yin L, Wang J, Klein PS, Lazar MA (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311(5763):1002\u20131005","journal-title":"Science"},{"issue":"3","key":"2008_CR20","doi-asserted-by":"publisher","first-page":"e33292","DOI":"10.1371\/journal.pone.0033292","volume":"7","author":"J Li","year":"2012","unstructured":"Li J, Lu WQ, Beesley S, Loudon AS, Meng QJ (2012) Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS ONE 7(3):e33292","journal-title":"PLoS ONE"},{"issue":"6","key":"2008_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/0748730411419775","volume":"26","author":"AS Johansson","year":"2011","unstructured":"Johansson AS, Brask J, Owe-Larsson B, Hetta J, Lundkvist GB (2011) Valproic acid phase shifts the rhythmic expression of Period2::Luciferase. J Biol Rhythms 26(6):541\u2013551","journal-title":"J Biol Rhythms"},{"issue":"18","key":"2008_CR22","doi-asserted-by":"publisher","first-page":"8399","DOI":"10.1073\/pnas.1004368107","volume":"107","author":"K Shimomura","year":"2010","unstructured":"Shimomura K, Lowrey PL, Vitaterna MH, Buhr ED, Kumar V, Hanna P, Omura C, Izumo M, Low SS, Barrett RK et al (2010) Genetic suppression of the circadian clock mutation by the melatonin biosynthesis pathway. Proc Natl Acad Sci U S A 107(18):8399\u20138403","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2008_CR23","doi-asserted-by":"crossref","unstructured":"Kandalepas PC, Mitchell JW, Gillette MUG (2016) Melatonin signal transduction pathways require E-Box-Mediated transcription of Per1 and Per2 to reset the SCN clock at dusk. PLoS ONE 11(6, pmid\u2009=\u200927362940).","DOI":"10.1371\/journal.pone.0157824"},{"issue":"6453","key":"2008_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.aax7621","volume":"365","author":"MD Ruben","year":"2019","unstructured":"Ruben MD, Smith DF, FitzGerald GA, Hogenesch JB (2019) Dosing time matters. Science 365(6453):547\u2013549","journal-title":"Science"},{"issue":"6","key":"2008_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/07420528.2021.1892127","volume":"38","author":"MJ Burish","year":"2021","unstructured":"Burish MJ, Han C, Mawatari K, Wirianto M, Kim E, Ono K, Parakramaweera R, Chen Z, Yoo SH (2021) The first-line cluster headache medication verapamil alters the circadian period and elicits sex-specific sleep changes in mice. Chronobiol Int 38(6):839\u2013850","journal-title":"Chronobiol Int"},{"issue":"1","key":"2008_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1073\/pnas.1118034108","volume":"109","author":"Z Chen","year":"2012","unstructured":"Chen Z, Yoo SH, Park YS, Kim KH, Wei S, Buhr E, Ye ZY, Pan HL, Takahashi JS (2012) Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. Proc Natl Acad Sci U S A 109(1):101\u2013106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2008_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.pain.2013.10.004","volume":"155","author":"AA Pradhan","year":"2014","unstructured":"Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269\u2013274","journal-title":"Pain"},{"issue":"15","key":"2008_CR28","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1021\/jm00041a001","volume":"37","author":"JW Clitherow","year":"1994","unstructured":"Clitherow JW, Scopes DI, Skingle M, Jordan CC, Feniuk W, Campbell IB, Carter MC, Collington EW, Connor HE, Higgins GA et al (1994) Evolution of a novel series of [(N,N-dimethylamino)propyl]- and Piperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem 37(15):2253\u20132257","journal-title":"J Med Chem"},{"issue":"10","key":"2008_CR29","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.pain.2011.07.002","volume":"152","author":"AR Charbit","year":"2011","unstructured":"Charbit AR, Akerman S, Goadsby PJ (2011) Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. Pain 152(10):2365\u20132376","journal-title":"Pain"},{"issue":"1","key":"2008_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65\u201373","journal-title":"J Psychopharmacol"},{"issue":"21","key":"2008_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/S0024-3205(02)02077-5","volume":"71","author":"M Ishiguro","year":"2002","unstructured":"Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T (2002) Identification of binding sites of Prazosin, Tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci 71(21):2531\u20132541","journal-title":"Life Sci"},{"issue":"3","key":"2008_CR32","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bmc.2011.12.019","volume":"20","author":"K Peprah","year":"2012","unstructured":"Peprah K, Zhu XY, Eyunni SV, Setola V, Roth BL, Ablordeppey SY (2012) Multi-receptor drug design: haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem 20(3):1291\u20131297","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2008_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78(1):189\u2013225","journal-title":"Physiol Rev"},{"issue":"40","key":"2008_CR34","doi-asserted-by":"publisher","first-page":"12532","DOI":"10.1523\/JNEUROSCI.2887-09.2009","volume":"29","author":"AR Charbit","year":"2009","unstructured":"Charbit AR, Akerman S, Holland PR, Goadsby PJ (2009) Neurons of the dopaminergic\/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci 29(40):12532\u201312541","journal-title":"J Neurosci"},{"issue":"1","key":"2008_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s002130100742","volume":"156","author":"MJ Millan","year":"2001","unstructured":"Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D (2001) The selective dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology 156(1):58\u201362","journal-title":"Psychopharmacology"},{"issue":"2","key":"2008_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0014-2999(85)90756-3","volume":"111","author":"H Hall","year":"1985","unstructured":"Hall H, K\u00f6hler C, Gawell L (1985) Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur J Pharmacol 111(2):191\u2013199","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"2008_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/0333102401021s0104","volume":"21","author":"C Dahlof","year":"2001","unstructured":"Dahlof C (2001) Clinical efficacy and tolerability of Sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia 21(Suppl 1):9\u201312","journal-title":"Cephalalgia"},{"issue":"1","key":"2008_CR38","first-page":"17","volume":"22","author":"S Miljkovi\u0107","year":"2018","unstructured":"Miljkovi\u0107 S, Smajlovi\u0107 D, Tiri\u0107 Campara M, Jurina R, Duranovi\u0107 Vinkovi\u0107 L, Jankovi\u0107 SM, Begovi\u0107 B, \u0106erani\u0107 M (2018) The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and Sumatriptan in migraine without aura. Hippokratia 22(1):17\u201322","journal-title":"Hippokratia"},{"issue":"11","key":"2008_CR39","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL (2022) The neural basis of psychedelic action. Nat Neurosci 25(11):1407\u20131419","journal-title":"Nat Neurosci"},{"issue":"10","key":"2008_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC (2022) Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache 62(10):1383\u20131394","journal-title":"Headache"},{"issue":"9","key":"2008_CR41","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","volume":"30","author":"M Karst","year":"2010","unstructured":"Karst M, Halpern JH, Bernateck M, Passie T (2010) The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 30(9):1140\u20131144","journal-title":"Cephalalgia"},{"issue":"7","key":"2008_CR42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.12866","volume":"56","author":"MS Robbins","year":"2016","unstructured":"Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016) Treatment of cluster headache: the American headache society Evidence-Based guidelines. Headache 56(7):1093\u20131106","journal-title":"Headache"},{"issue":"Suppl 2","key":"2008_CR43","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s10194-012-0437-6","volume":"13","author":"P Sarchielli","year":"2012","unstructured":"Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, Pinessi L, Alessandri M, Antonaci F, Fanciullacci M et al (2012) Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 13(Suppl 2):S31\u201370","journal-title":"J Headache Pain"},{"issue":"10","key":"2008_CR44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1526-4610.2004.04196.x","volume":"44","author":"JN Blau","year":"2004","unstructured":"Blau JN, Engel HO (2004) Individualizing treatment with verapamil for cluster headache patients. Headache 44(10):1013\u20131018","journal-title":"Headache"},{"issue":"5","key":"2008_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41582-021-00477-w","volume":"17","author":"DY Wei","year":"2021","unstructured":"Wei DY, Goadsby PJ (2021) Cluster headache pathophysiology - insights from current and emerging treatments. Nat Rev Neurol 17(5):308\u2013324","journal-title":"Nat Rev Neurol"},{"issue":"5488","key":"2008_CR46","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1126\/science.289.5488.2344","volume":"289","author":"A Balsalobre","year":"2000","unstructured":"Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, Sch\u00fctz G, Schibler U (2000) Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 289(5488):2344\u20132347","journal-title":"Science"},{"issue":"Pt 1","key":"2008_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, Saxena PR, Dahl\u00f6f C, Pascual J, L\u00e1inez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000) Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(Pt 1):9\u201318","journal-title":"Brain"},{"key":"2008_CR48","doi-asserted-by":"crossref","unstructured":"Dahlf Ca, (2012) Dihydroergotamine, ergotamine, methysergide and sumatriptan - Basic science in relation to migraine treatment. Headache 52: 707\u2013714, pmid\u2009=\u200922444161","DOI":"10.1111\/j.1526-4610.2012.02124.x"},{"issue":"12","key":"2008_CR49","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14656566.2013.806487","volume":"14","author":"MB Ramirez Rosas","year":"2013","unstructured":"Ramirez Rosas MB, Labruijere S, Villalon CM, Maassen Vandenbrink A (2013) Activation of 5-hydroxytryptamine1B\/1D\/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother 14(12):1599\u20131610","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20132","key":"2008_CR50","first-page":"337","volume":"73","author":"A Fletcher","year":"1996","unstructured":"Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ et al (1996) Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73(1\u20132):337\u2013353","journal-title":"Behav Brain Res"},{"issue":"3","key":"2008_CR51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/PL00005056","volume":"356","author":"GW Price","year":"1997","unstructured":"Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, G\u00f6thert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN (1997) SB-216641 and BRL-15572\u2013compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 356(3):312\u2013320","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2008_CR52","doi-asserted-by":"crossref","unstructured":"Skingle et al (1996) GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res 73(1-2):157\u2013161. https:\/\/pubmed.ncbi.nlm.nih.gov\/8788495\/","DOI":"10.1016\/0166-4328(96)00089-7"},{"issue":"8","key":"2008_CR53","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1021\/jm970457s","volume":"41","author":"LM Gaster","year":"1998","unstructured":"Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR et al (1998) The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 41(8):1218\u20131235","journal-title":"J Med Chem"},{"key":"2008_CR54","doi-asserted-by":"crossref","unstructured":"Tfelt-Hansen, Pa (2000) Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60: 1259\u20131287, pmid\u2009=\u200911152011","DOI":"10.2165\/00003495-200060060-00003"},{"issue":"2","key":"2008_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.bjp.0701041","volume":"121","author":"GR Martin","year":"1997","unstructured":"Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S (1997) Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B\/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 121(2):157\u2013164","journal-title":"Br J Pharmacol"},{"issue":"21","key":"2008_CR56","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0024-3205(97)00885-0","volume":"61","author":"LA Phebus","year":"1997","unstructured":"Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD Jr., Branchek TA et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61(21):2117\u20132126","journal-title":"Life Sci"},{"issue":"3","key":"2008_CR57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/jpet.117.239905","volume":"361","author":"AA Jensen","year":"2017","unstructured":"Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Br\u00e4uner-Osborne H, Kehler J, Kristensen JL (2017) Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of N-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT(2A) Receptor Agonist. J Pharmacol Exp Ther 361(3):441\u2013453","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2008_CR58","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.bjp.0702632","volume":"127","author":"DW Bonhaus","year":"1999","unstructured":"Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A et al (1999) RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol 127(5):1075\u20131082","journal-title":"Br J Pharmacol"},{"issue":"4\u20135","key":"2008_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","volume":"36","author":"GA Kennett","year":"1997","unstructured":"Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S et al (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36(4\u20135):609\u2013620","journal-title":"Neuropharmacology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02008-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T08:03:08Z","timestamp":1747987388000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02008-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02008-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by UTHealth Houston (protocol AWC-23-0038).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethnics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Burish has served as a consultant for Lundbeck, Pfizer, and PureTech Health, a site investigator for a cluster headache clinical trial funded by Lundbeck, a paid guest for a video podcast by the American Academy of Neurology, and an unpaid member of the medical advisory board of Clusterbusters. All other authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}